PLURISTEM THERAPEUTICS INC - FORM 10-K - EX-32.2 - CERTIFICATION - September 10, 2020

Attached files

file filename
EX-4.3 - DESCRIPTION OF SECURITIES - PLURISTEM THERAPEUTICS INCf10k2020ex4-3_pluristem.htm
10-K - ANNUAL REPORT - PLURISTEM THERAPEUTICS INCf10k2020_pluristemtherap.htm
EX-32.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2020ex32-1_pluristem.htm
EX-31.2 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2020ex31-2_pluristem.htm
EX-31.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2020ex31-1_pluristem.htm
EX-23.1 - CONSENT OF KOST FORER GABBAY & KASIERER, A MEMBER OF ERNST & YOUNG GLOBAL - PLURISTEM THERAPEUTICS INCf10k2020ex23-1_pluristem.htm
EX-21.1 - LIST OF SUBSIDIARIES OF THE COMPANY - PLURISTEM THERAPEUTICS INCf10k2020ex21-1_pluristem.htm
EX-10.20 - FINANCE CONTRACT BETWEEN THE EUROPEAN INVESTMENT BANK, AS LENDER, AND PLURISTEM - PLURISTEM THERAPEUTICS INCf10k2020ex10-20_pluristem.htm
EX-10.19 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT BETWEEN PLURISTEM LTD. AND CHEN FRANCO - PLURISTEM THERAPEUTICS INCf10k2020ex10-19_pluristem.htm
EX-10.18 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT BETWEEN PLURISTEM LTD. AND YAKY YANAY - PLURISTEM THERAPEUTICS INCf10k2020ex10-18_pluristem.htm
EX-10.17 - AMENDED AND RESTATED CONSULTING AGREEMENT BETWEEN PLURISTEM LTD. AND ROSE HIGH T - PLURISTEM THERAPEUTICS INCf10k2020ex10-17_pluristem.htm
EX-10.8 - SUMMARY OF DIRECTORS' ONGOING COMPENSATION - PLURISTEM THERAPEUTICS INCf10k2020ex10-8_pluristem.htm
EX-3.4 - AMENDED AND RESTATED BY-LAWS AS AMENDED ON SEPTEMBER 10, 2020 (MARKED) - PLURISTEM THERAPEUTICS INCf10k2020ex3-4_pluristem.htm
EX-3.3 - AMENDED AND RESTATED BY-LAWS AS AMENDED ON SEPTEMBER 10, 2020 - PLURISTEM THERAPEUTICS INCf10k2020ex3-3_pluristem.htm

Exhibit 32.2

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350

 

In connection with the Annual Report on Form 10-K of Pluristem Therapeutics Inc. (the “Company”) for the period ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350 that, to my knowledge:

 

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date:  September 10, 2020  
   
  By: /s/ Chen Franco-Yehuda
    Chen Franco-Yehuda
    Chief Financial Officer

  

PLURISTEM THERAPEUTICS INC Reports